Research Report
Stephane Foucaud (03/31/2026)
Auctus Advisors raised its target price on New Zealand Energy Corp. (NZ:TSX.V; NZERF:OTCQX) after the Ngaere-2 well recompletion delivered 300 bbl/d, exceeding expectations. Research Report
Dr. Yun Zhong (03/27/2026)
Wedbush Securities raised its price target on Sarepta Therapeutics Inc. (SRPT:NASDAQ), following promising Phase 1/2 data for siRNA candidates SRP-1001 in FSHD and SRP-1003 in DM1, citing superior muscle concentration and a clean safety profile versus rival programs from Novartis and Dyne Therapeutics. Research Report
Mitchell Kapoor (03/26/2026)
H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics Inc. (SRPT:NASDAQ), arguing that promising but early-stage siRNA muscle concentration data in DM1 and FSHD cannot compensate for falling ELEVIDYS sales, a fatal adverse event in SRP-1003, and intensifying competition from Avidity and Dyne ahead of a potential 2030 market entry. Research Report
Paul Matteis (03/25/2026)
Stifel reiterated its rating and price target on Alto Neuroscience Inc. (ANRO:NYSE) after an in-line Q4 2025 earnings report. Research Report
Patrick Trucchio (03/25/2026)
H.C. Wainwright reiterated its rating and price target on Alto Neuroscience Inc. (ANRO:NYSE), citing upcoming Phase 2 data readouts for ALTO-101, ALTO-300, and ALTO-100, plus US$120 million financing to advance ALTO-207 in treatment-resistant depression through Phase 3.